Lyophilization stabilizes clinical-stage core-crosslinked polymeric micelles to overcome cold chain supply challenges

Tarun Ojha¹,²,³ | Qizhi Hu⁴ | Claudio Colombo⁴ | Jan Wit⁵ | Michiel van Geijn⁴ | Mies J. van Steenbergen² | Mahsa Bagheri² | Hiltrud Königs-Werner⁶ | Eva Miriam Buhl⁶ | Ruchi Bansal¹,³ | Yang Shi¹ | Wim E. Hennink² | Gert Storm²,⁷ | Cristianne J. F. Rijcken⁴ | Twan Lammers¹,²,⁷

¹ Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
² Department of Pharmaceutics, Utrecht University, Utrecht, The Netherlands
³ Department of Medical Cell Biophysics, Faculty of Science and Technology, University of Twente, Translational Liver Research, Enschede, The Netherlands
⁴ Cristal Therapeutics, Maastricht, The Netherlands
⁵ Saudade Pharma Consultancy, Eijsden, The Netherlands
⁶ Electron Microscope Facility, University Hospital RWTH, RWTH Aachen University, Aachen, Germany
⁷ Department of Biomaterials, Science and Technology, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands

Correspondence
Twan Lammers, Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany. Email: tlammers@ukaachen.de
Cristianne J. F. Rijcken, Cristal Therapeutics, 6229 EV Maastricht, The Netherlands. Email: cristianne.rijcken@cristaltherapeutics.com

Abstract

Background: CriPec technology enables the generation of drug-entrapped biodegradable core-crosslinked polymeric micelles (CCPM) with high drug loading capacity, tailorable size, and drug release kinetics. Docetaxel (DTX)-entrapped CCPM, also referred to as CPC634, have demonstrated favorable pharmacokinetics, tolerability, and enhanced tumor uptake in patients. Clinical efficacy evaluation is ongoing. CPC634 is currently stored (shelf life > 5 years) and shipped as a frozen aqueous dispersion at temperatures below −60°C, in order to prevent premature release of DTX and hydrolysis of the core-crosslinks. Consequently, like other aqueous nanomedicine formulations, CPC634 relies on cold chain supply, which is unfavorable for commercialization. Lyophilization can help to bypass this issue.

Methods and results: Freeze-drying methodology for CCPM was developed by employing CPC634 as a model formulation, and sucrose and trehalose as cryoprotectants. We studied the residual moisture content and reconstitution behavior of the CPC634 freeze-dried cake, as well as the size, polydispersity index, morphology, drug retention, and release kinetics of reconstituted CPC634. Subsequently, the freeze-drying methodology was validated in an industrial setting, yielding a CPC634 freeze-dried cake with a moisture content of less than 0.1 wt%. It was found that trehalose-cryoprotected CPC634 could be rapidly reconstituted in less than 5 min at room temperature. Critical quality attributes such as size, morphology, drug retention, and release kinetics of trehalose-cryoprotected freeze-dried CPC634 upon reconstitution were identical to those of non-freeze-dried CPC634.

Conclusion: Our findings provide proof-of-concept for the lyophilization of drug-containing CCPM and our methodology is readily translatable to large-scale manufacturing for future commercialization.
1 | INTRODUCTION

Polymeric micelles (PM) can entrap drug molecules either via physical interaction (e.g., hydrophobic interactions and π-π stacking) or via chemical interaction (e.g., covalent core-crosslinking), and they are attractive vehicles for targeted drug delivery to pathological sites exploiting the so-called EPR effect. PM based on CriPec technology platform are size-tunable (30–100 nm) core-crosslinked polymeric micelles (CCPM) composed of thermosensitive methoxy poly(ethylene glycol)-b-poly[N-(2-hydroxypropyl) methacrylamide lactate] (mPEG-b-pHPMAmLac) block copolymers. During the manufacturing of CCPM, the block copolymers self-assemble into micellar structures in aqueous solutions and then crosslinked in the micellar core by means of free radical polymerization. Meanwhile, drug molecules are transiently covalently attached to the crosslinked micellar core via hydrolysable linkages that enable release of native drug molecules at the target site with predetermined kinetics. Covalent core-crosslinking of PM prevents premature micelle disintegration and minimizes drug release in the bloodstream, together contributing to prolonged circulation and enhanced drug delivery to pathological sites. So far, a variety of therapeutics agents such as chemotherapeutic drugs, corticosteroids, and peptides have been successfully entrapped in CCPM, resulting in superior therapeutic performance.

Docetaxel (DTX)-entrapped CCPM, also known as CPC634, is the clinically most advanced CriPec nanomedicine where DTX is conjugated via a hydrolytically sensitive ester bond to the core of the micelles. CPC634 is currently under evaluation in a phase 2 clinical trial in patients with ovarian cancer (NCT02442531: NAPOLY). In the clinically used formulation, the DTX-entrapped CCPM are dispersed in an aqueous buffer. However, the formulation cannot be stored in the fridge (4°C) for prolonged periods of time because of inherent hydrolysis of the ester bond between DTX and the CCPM and thereby premature release of the drug. Consequently, the clinical batches of CPC634 are stored at less than −60°C as a frozen dispersion. So far, CPC634 aqueous formulation has demonstrated good stability for at least 5 years upon storage at less than −60°C.

Currently, the supply of CPC634 to clinics relies on a cold chain comprising of shipment on dry ice, continuous temperature logging, and less than −60°C freezers at each clinical site, all contributing to a very expensive mode of transportation. To circumvent this, we developed a freeze-drying process for lyophilization of CPC634 which likely can also be exploited for other (CriPec) nanoformulations. Freeze-drying is a water removal process by sublimation of ice under high vacuum, which offers long shelf-life and ease of transportation of pharmaceutical and food products. Freeze-drying has already been employed for CCPM and several other PM nanoformulations (e.g., Genexol-PM, NK105, and NK-6004 Nanoplatin), as well as used for stabilization of other nanomedicine formulations such as liposomes and lipo/polyplexes. A freeze-drying process typically involves three steps: (1) freezing; (2) primary drying, i.e., removal of bulk water molecules; and (3) secondary drying, i.e., removal of residual/bound water molecules. For therapeutic proteins and nano-formulations, harsh treatments such as freezing and drying can deform, damage, and even disintegrate them, thus compromising their pharmaceutical properties. Cryoprotectants, which comprise sugars, polymers, and surfactants, are commonly used to stabilize the formulation, by means of vitrification. Additionally, sugars provide cryoprotection via water replacement mechanism, i.e., hydrogen bonding between hydroxyl groups of sugar and hydrogen accepting groups in proteins and PE-Gylated nanoparticles. For each formulation, an individually optimized protocol is needed to identify the best cryoprotectant, concentration, and freeze-drying settings (including vacuum pressure, temperature, and duration) to eventually obtain a freeze-dried product with unaltered physicochemical and pharmaceutical properties after reconstitution.

In the present study, efforts to establish cryoprotectant selection and freeze-drying settings for obtaining lyophilized DTX-entrapped CCPM are described (Figure 1). An aqueous dispersion of CPC634 was employed as the starting formulation. Standard cryoprotectants based on sugars were assessed and two different shelf freeze-dryers were used. Further, differential scanning calorimetry (DSC) was employed to determine glass transition temperature (T_g) of CPC634 aqueous dispersion containing different cryoprotectants. Extensive post-freeze-drying characterizations, evaluating cake appearance, residual moisture content, reconstitution behavior, size, polydispersity index (PDI), drug retention, and drug release kinetics were performed.

2 | MATERIALS AND METHODS

2.1 Materials

DTX was obtained from Phyton Biotech GmbH (Arensburg, Germany). N,N'-dicyclohexyl-carbodiimide (DCC), 4-dimethylaminopyridine, 4-methoxyphenol, methacrylic anhydride,
ammonium acetate, formic acid, Mukaiyama’s reagent (2-chloro-1-methylpyridinium iodide), potassium peroxymonosulfate (oxone), potassium persulfate (KPS), lactic acid, N, N, N’, N’ tetramethylethylenediamine (TEMED), and trifluoroacetic acid were obtained from Sigma Aldrich (Zwijndrecht, The Netherlands). Dichloromethane, N,N-dimethylformamide, and acetonitrile (ACN) were purchased from Biosolve (Valkenswaard, The Netherlands). Absolute ethanol and triethylamine were purchased from Merck (Darmstadt, Germany). Absolute ethanol and triethylamine were purchased from Merck (Darmstadt, Germany). A total of 3-mL sample glass vials (soda-lime glass) with silicon caps were purchased from VWR (Langenfeld, Germany). All materials were analytical grade and used without purification.

### 2.2 Preparation of CPC634 dispersion

The detailed synthesis of derivatized DTX and CPC634 is described in \(^4\). Briefly, an ice-cold aqueous solution of methacrylated mPEG5000-b-pHPMAmLacn \((n = 1 \text{ or } 2, 22.6 \text{ kDa})\) block copolymer (83 v%, 24 mg mL\(^{-1}\)) was mixed with TEMED (2.5 v%, 120 mg mL\(^{-1}\)) dissolved in ammonium acetate buffer (150 mM, pH 5). Subsequently, derivatized DTX (10 v%, 20 mg mL\(^{-1}\) DTX equivalents) was added, followed by rapid heating to 60°C under vigorous stirring for 1 min to form micelles. The micellar aqueous dispersion was then transferred into a vial containing KPS (4.5 v%, 30 mg mL\(^{-1}\)) dissolved in ammonium acetate buffer (150 mM, pH 5). The PM were covalently stabilized by free radical polymerization of the methacrylate moieties of derivatized DTX and methacrylated mPEG-b-pHPMAmLacn under a N\(_2\) atmosphere for 1 h at room temperature, to obtain CPC634 micelles. The final feed concentrations of block copolymer and DTX equivalents were 20 and 2.0 mg mL\(^{-1}\), respectively. Next, the obtained CPC634 dispersion was filtered through a 0.2 \(\mu\)m cellulose membrane filter to remove possible aggregates, and then purified in ammonium acetate buffer (20 mM, pH 5, supplemented with 130 mM NaCl) using a KrosFlo Research IIIi Tangential Flow Filtration (TFF) System equipped with modified polyethersulfone MicroKros filter modules (MWCO 100 kDa). The chemical structures and schematics of methacrylated mPEG5000-b-pHPMAmLacn, block copolymer, derivatized DTX, and CPC634 are illustrated in Figure S1, Supporting Information. To prepare materials for freeze-drying experiments, a clinical batch of CPC634 (2 mg mL\(^{-1}\) DTX equiv) was buffer swapped into predetermined aqueous solutions, followed by concentration to 15 mg mL\(^{-1}\) DTX equiv. (135 mg mL\(^{-1}\) polymer equiv) by TFF and subsequent storage at less than –60°C.

### 2.3 Differential DSC analysis

Determination of \(T_g\) of CPC634 aqueous dispersions (block copolymer and derivatized DTX (DTX equivalents)) concentration were (109 and 12 mg mL\(^{-1}\), respectively) in sodium acetate buffer (20 mM, pH 5) with
two cryoprotectants (sucrose and trehalose 10 wt%) using a TA Instruments Discovery DSC device was done as follows. A total of 20 μL of CPC634 cryoprotectant dispersion was added in hermetic aluminum pan that was sealed with aluminum lid. The pan containing the sample was frozen to −70°C and then gradually heated to 50°C at a rate of 10°C min⁻¹, followed by cooling down again to −70°C and re-heating to 50°C, always at a rate of 10°C min⁻¹. A pan containing 20 μL water was used as reference. The Tg was determined with the help of TRIOS software. The reported Tg values were obtained from the last heat unloading. The above freeze-drying cycle parameters (shelf temperature and vacuum pressure) were selected based on trial freeze-drying experiments, conducted at different vacuum pressure (0.1, 0.2, and 0.3 mbar) and at different shelf temperatures (−25°C, −30, and −70°C) and re-heating was carried by adjusting shelf temperature to −25°C. Freezing of the dispersions was initiated by setting the shelf-temperature at −45°C for 3 h at atmospheric pressure. This was followed by primary freeze-drying at −25°C shelf temperature and −70°C condenser temperature under 0.3 mbar chamber pressure for 17 h. Subsequently, secondary drying was conducted at shelf temperature 20°C and a condenser temperature of −70°C at 0.3 mbar for 4 h. Lastly, the chamber pressure was adjusted back to atmospheric pressure and the vials were sealed in the freeze-dryer with silicon caps prior to unloading. The above freeze-drying cycle parameters (shelf temperature and vacuum pressure) were selected based on trial freeze-drying experiments, conducted at different vacuum pressure (0.1, 0.2, and 0.3 mbar) and at different shelf temperatures (−35, −30, and −25°C) and by hourly recording product temperature using integrated temperature sensor needles inserted in the vials.

Further development of the CCPM freeze-drying process was conducted in an industrial setting. Using a GT3 shelf freeze-dryer (Hof Sonderanlagenbau GmbH, Lohra, Germany) equipped with a Pirani gauge sensor, a Baratron capacitance manometer for vacuum pressure measurement and a product temperature sensor. Glass vials filled with 1 mL samples (each vial containing 12 mg of DTX, 70 mg block copolymer, and trehalose 5 wt%) were sealed with steam permeable LyoProtect bags to avoid contamination from the freeze-dryer and were further loaded on the freeze-dryer shelf with a temperature of 20°C. Freezing was carried by adjusting shelf temperature to −45°C for 4 h. Subsequently, primary drying was conducted at −10°C shelf temperature and −70°C condenser temperature at 0.05 mbar for 33 h. Next, secondary drying was conducted by ramping the shelf temperature to 30°C and keeping the condenser temperature and vacuum pressure unaltered for 18 h. Vials were sealed with caps under nitrogen at 750 mbar chamber pressure before unloading the vials from the freeze-dryer.

The freeze-dried CPC634 samples were reconstituted with 2 mL of 0.9% NaCl solution. After addition of the NaCl solution, the vials were left undisturbed on the shelf while observing their reconstitution behavior. Complete dissolution of the freeze-dried CCPM cake was examined visually and the time for complete dissolution was established. Following this, pH of reconstituted samples was measured with Five Easy pH meter (Mettler Toledo BV, Tiel, The Netherlands).

2.4 Freeze-drying and reconstitution

Freeze-drying of CPC634 was carried out using LyoPride 03, a pilot-scale shelf freeze-dryer (IshinBioBase, Dongduchon, South Korea) equipped with a temperature sensor for recording the product temperature. A total of 3-mL glass vials were filled with 1 mL of CPC634 aqueous dispersion in sodium acetate buffer (20 mM, pH 5) containing 12 mg of derivatized DTX (DTX equivalents), 109 mg block copolymer, and different cryoprotectants (sucrose and trehalose) at different weight ratios (10, 5, and 2.5 wt%). The glass vials (partially capped with silicon caps) were loaded in the freeze-dryer onto the stainless-steel shelf set at 4°C. Freezing of the dispersions was initiated by setting the shelf-temperature at −45°C for 3 h at atmospheric pressure. This was followed by primary freeze-drying at −25°C shelf temperature and −70°C condenser temperature under 0.3 mbar chamber pressure for 17 h. Subsequently, secondary drying was conducted at shelf temperature 20°C and a condenser temperature of −70°C at 0.3 mbar for 4 h. Lastly, the chamber pressure was adjusted back to atmospheric pressure and the vials were sealed in the freeze-dryer with silicon caps prior to unloading. The above freeze-drying cycle parameters (shelf temperature and vacuum pressure) were selected based on trial freeze-drying experiments, conducted at different vacuum pressure (0.1, 0.2, and 0.3 mbar) and at different shelf temperatures (−35, −30, and −25°C) and by hourly recording product temperature using integrated temperature sensor needles inserted in the vials.

Further development of the CCPM freeze-drying process was conducted in an industrial setting. Using a GT3 shelf freeze-dryer (Hof Sonderanlagenbau GmbH, Lohra, Germany) equipped with a Pirani gauge sensor, a Baratron capacitance manometer for vacuum pressure measurement and a product temperature sensor. Glass vials filled with 1 mL samples (each vial containing 12 mg of DTX, 70 mg block copolymer, and trehalose 5 wt%) were sealed with steam permeable LyoProtect bags to avoid contamination from the freeze-dryer and were further loaded on the freeze-dryer shelf with a temperature of 20°C. Freezing was carried by adjusting shelf temperature to −45°C for 4 h. Subsequently, primary drying was conducted at −10°C shelf temperature and −70°C condenser temperature at 0.05 mbar for 33 h. Next, secondary drying was conducted by ramping the shelf temperature to 30°C and keeping the condenser temperature and vacuum pressure unaltered for 18 h. Vials were sealed with caps under nitrogen at 750 mbar chamber pressure before unloading the vials from the freeze-dryer.

The freeze-dried CPC634 samples were reconstituted with 2 mL of 0.9% NaCl solution. After addition of the NaCl solution, the vials were left undisturbed on the shelf while observing their reconstitution behavior. Complete dissolution of the freeze-dried CCPM cake was examined visually and the time for complete dissolution was established. Following this, pH of reconstituted samples was measured with Five Easy pH meter (Mettler Toledo BV, Tiel, The Netherlands).

2.5 Moisture content analysis

The moisture content of the CPC634 freeze-dried cakes was analyzed using a TA Instruments—TGA Q50 device. Around 10 mg of the freeze-dried sample (accurately weighed) was loaded into platinum pan. The pan was placed on the sample holder followed by heating to 110°C for 8 min in the instrument’s furnace. The change in wt% after heat treatment was used to calculate the moisture content of the freeze-dried cakes. The measurements were conducted in triplicates. For the industrial setting experiments, the residual moisture content of the samples was determined via Karl Fischer titration using a 756 Karl Fischer coulometer (Deutsch Metrohm GmbH, Filderstadt, Germany). For each measurement, around 100 mg of each lyophilizate was accurately weighed and transferred into a Karl-Fischer glass vial. The vial was sealed with a crimp cap and transferred into the oven of the Karl Fischer coulometer that was heated to 100°C for 5 min. The septum of the cap was penetrated by an injection needle, and the generated water vapor was transferred into the titration chamber of the Karl Fischer coulometer by a dry nitrogen flow. Empty glass vials were used for blank correction. The measurements were conducted in duplicate.

2.6 Size measurements

The samples for size measurements were prepared by diluting reconstituted CPC634 samples by 100 folds with Millipore water. The size of the micelles was measured by dynamic light scattering (DLS) using a Malvern Zetasizer nano series ZS90 with a measurement angle of 90° and a temperature of 25°C. DLS results are presented as z-average particle size diameter and PDI. For each sample, the reported values are the average of 3 independent measurements. Morphological analysis of CPC634 was performed using transmission electron microscope (TEM). For sample preparation, CPC634 particles were allowed to adsorb on glow-discharged formvar-carbon-coated nickel grids (Maxtaform, 200 mesh, Plano, Wetzlar, Germany) for 10 min. Negative staining was performed with 0.5% uranyl acetate (Science Services GmbH, Munich, Germany). Samples were examined using a TEM LEO 906 (Carl Zeiss, Oberkochen, Germany), operating at an acceleration voltage of 60 kV. Particle size was determined from TEM image using ImageSP software (SYSPROG, Belarus).
2.7 | Drug retention and drug release kinetics analysis

The amounts of DTX and 7-epi-DTX (epimer of DTX) in aqueous dispersions of CPC634 were determined by ultra-performance liquid chromatography (UPLC). Drug release kinetics analysis was performed according to a previously established protocol.[7] Release of DTX from CPC634 was studied in phosphate buffer (100 mM, pH 7.4), containing 33 mM NaCl and 1% polysorbate 80 v/v (to solubilize released DTX and 7-epi DTX) at 37°C. CPC634 dispersion was incubated at 37°C and the samples were collected at different time points and analyzed for released DTX using UPLC. The concentration of released DTX and 7-epi DTX was determined by injecting 7 μL of the mixture into a UPLC system (Waters, USA) equipped with an ultraviolet/visible light detector (DAD, Waters). An Acquity HSS T3 1.8 μm, 2.1 × 50 mm column (Waters) was used with a gradient from 100% eluent A (70% H2O/30% ACN/0.1% formic acid %v/v/v) to 100% B (10% H2O/90% ACN/0.1% formic acid % v/v/v) in 14 min with a flow rate of 0.7 mL min^{-1} and UV detection at 227 nm. DTX standards dissolved in 70% v/v ACN at a concentration of 50 μg mL\(^{-1}\) were used for quantification. Released DTX was calculated based on total DTX levels present in the formulation. The latter was determined by a separate assay that is based on full conversion of DTX present in CPC634 into a stable final degradation product benzoic acid under strongly basic conditions followed by chromatographic separation and UV detection.

2.8 | Statistical analysis

Statistical analysis was performed using GraphPad Prism 8 (GraphPad Software Inc., San Diego, CA, USA). The two-tailed Student’s t test and the Mann–Whitney U test were used for the analysis. A p-values of <0.05 was considered to be statistically significant.

3 | RESULTS AND DISCUSSION

3.1 | T\(_g\) and freeze-drying of CPC634

CPC634 micelles were freeze-dried using sucrose and trehalose as cryoprotectant, both at 10 wt%. DSC analysis of the resulting dispersions was done to determine the T\(_g\) of the systems since this is an important parameter for the development of the desired freeze-dried product. Especially for nanoformulations, carrying out the primary drying at temperatures above the T\(_g\) can result in structural deformation and/or aggregation as a result of defects in the freeze-dried cake.[13,23]

Figure 2A shows T\(_g\) values of CPC634-cryoprotectant dispersions obtained by DSC heat/cool/heat analysis. The T\(_g\) of the CPC634-trehalose dispersion was slightly higher than that of the CPC634-sucrose dispersion (−32.8 and −35.1°C, respectively). As illustrated in Figure 2B, a conventional three-step freeze-drying procedure, i.e., freezing, primary drying, and secondary drying, using a Lyoph-Pride 03 pilot scale shelf freeze-dryer was employed. Based on the obtained T\(_g\) values, specifically considering CPC634-trehalose T\(_g\), the vacuum pressure and shelf temperature was adjusted to keep the product temperature below the T\(_g\) of the frozen dispersions during early hours of primary drying (Figure 2B).

Based on the freeze-drying cycle optimization experiments, it was found that primary drying works best at a chamber pressure 0.3 mbar and at a shelf temperature −25°C, applied for 17 h. The endpoint of primary drying is ideally decided when decline in chamber vapor pressure reached the lowest possible level and when product temperature reaches that of the shelf.[30] Vapor pressure is usually measured by a built-in Pirani gauge sensor, but since the freeze-dryer did not have such a sensor, the overlap of product and shelf temperature were considered as an endpoint of the primary drying. Secondary drying was carried out by ramping up the shelf temperature to 20°C for 4 h, to
3.2 Effect of freeze-drying on CPC634 size, PDI, and morphology

The freeze-dried CPC634-trehalose, CPC634-sucrose, and non-cryoprotected CPC634 cakes were well-defined with no obvious defects (cracks, shrinking) (Figure 3A). The samples were reconstituted with 2 mL of 0.9% NaCl solution without applying any external force, such as shaking or vortexing. The freeze-dried cakes cryoprotected with trehalose and sucrose contained 1.46 and 1.53 wt% residual moisture, respectively. After reconstitution, the non-cryoprotected CPC634 sample was turbid with visible precipitates (Figure 3B), demonstrating that the use of a cryoprotectant is required. In comparison, reconstitution of freeze-dried CPC634-trehalose and CPC634-sucrose samples was completed in less than 5 min and in 15 min, respectively. In both cases, the reconstituted dispersions were opalescent and homogenous with a pH of 5.1, alike the aqueous formulations before freeze-drying (Figure 3B).

DLS measurements showed that after reconstitution, there was no change in the mean size, size distribution, and PDI of CPC634 cryoprotected with 10 wt% trehalose when compared to the non-freeze-dried particles (Figure 3C,D and Figure S2A, Supporting Information). Conversely, a statistically significant increase in the mean size (from 65 to 85 nm) and PDI (from 0.10 to 0.18) of CPC634 cryoprotected with sucrose 10 wt% was observed (Figure 3C,D). Similarly, DLS size distribution analysis indicated increase in size of CPC634 cryoprotected with sucrose 10 wt% (Figure S2A, Supporting Information). Due to substantial aggregation, DLS measurements were not performed on the reconstituted non-cryoprotected micelles.

The TEM images of Figure 3E–H illustrated the morphology of a non-freeze-dried CPC634 control formulation, reconstituted CPC634 cryoprotected with trehalose and sucrose, as well as reconstituted non-cryoprotected CPC634. In line with the DLS findings, the TEM images and size analysis clearly demonstrated that the mean size, size distribution, and shape of trehalose protected CPC634 were identical to those of the parental non-freeze-dried control formulation (Figure 3C,F and Figure S2A,C, Supporting Information). Analogously, the TEM images of CPC634 cryoprotected with sucrose showcased the increase in the mean size and size distribution, which was also observed using DLS (Figure 3G and Figure S2C, Supporting Information).

remove bound water molecules from the CCPM cake. The endpoint of the secondary drying was also determined based on time point where both product as well as shelf temperature were the same.
FIGURE 4  Analysis of drug retention and in vitro drug release kinetics, as well as size, PDI, and morphology upon using low amounts of cryoprotectants. (A) The amount of free DTX plus 7-epi-DTX in reconstituted CPC634 cryoprotected with 10 wt% trehalose and sucrose as compared to non-freeze-dried/parental CPC634 control. (B) DTX release profile of parental CPC634 formulation (control) and reconstituted CPC634 cryoprotected with trehalose and sucrose under physiological conditions. (C, D) Sizes and PDI of reconstituted CPC634 cryoprotected with trehalose 5 and 2.5 wt%, determined by DLS analysis. Values represent mean ± SD of three different batches, measured in triplicates. (E, F) Representative TEM images of reconstituted CPC634 cryoprotected with 5 and 2.5 wt% trehalose

Information). The TEM images of non-cryoprotected CPC634 showed the formation of large aggregates of the CPC634 micelles.

Together, these results demonstrate that 10 wt% trehalose efficiently preserves the structural integrity of CPC634 during freeze-drying while 10 wt% sucrose was found to be less suitable for the freeze-drying of CPC634. This could be due to the fact that trehalose decreases water crystallization better than sucrose by having greater destructing effect on the tetrahedral structure of water than sucrose.[31,32] Furthermore, the primary freeze-drying settings (i.e., vacuum pressure and shelf temperature) used in our experiments together with the lower T_g of sucrose may have resulted in less uniform vitrification during freeze-drying, as the product temperature was very close to the T_g of sucrose, which could have led to the aggregation of micelles.[33]

3.3 | Effect of CPC634 freeze-drying on drug retention and release kinetics

Freeze-drying can affect the drug retention of nanomedicines by causing physical and mechanical stress. Since premature drug release of nanomedicine formulations is unwanted, the so-called burst release was quantified. The amounts of free DTX plus 7-epi-DTX (epimer of DTX, its main degradation product in aqueous solutions[34,35]) in reconstituted CPC634 cryoprotected with trehalose and sucrose was determined using UPLC.[7] Furthermore the in vitro drug release behavior of reconstituted CPC634 was evaluated under physiological conditions up to 192 h.

Figure 4A clearly demonstrates that the free DTX plus 7-epi-DTX content was identical in reconstituted CPC634 cryoprotected with either trehalose or sucrose compared to non-freeze-dried parental control CPC634. In line with this, investigation of the in vitro DTX release kinetics under physiological conditions (pH 7.4, 37 °C) revealed that freeze-drying with trehalose and sucrose had not affected the drug release kinetics of CPC634 compared to the parental control formulation (Figure 4B).

Together, these findings demonstrate that CPC634 drug retention and drug release kinetics are not affected by freeze-drying when cryoprotected with either trehalose 10 wt% or sucrose 10 wt%. CPC634 cryoprotected with sucrose showed a slight increase in size and PDI (Figure 3), but the freeze-drying process did not impact drug release kinetics given the latter is driven by chemical hydrolysis of the ester linkage between DTX and the CCPM. Conversely, freeze-drying of several nanoformulations incorporating physically bound drug showed not only increased size and PDI, but also noticeable drug leakage and altered (faster) drug release profile.[36–38] In contrast
to these physical assemblies, CPC634 is a core-crosslinked nanoparticle with covalent DTX entrapment with initial structural integrity and a well-defined biodegradable profile over time under physiological conditions. The findings of Figure 4B indicate that core-crosslinking of CPC634 prevented drug leakage. More specifically, during the freeze-drying process, the low moisture content and temperature prevented premature hydrolysis of the ester bond linking DTX and CCPM core.

### 3.4 CPC634 freeze-drying using lower cryoprotectant amounts

The above results demonstrate better performance of trehalose over sucrose in protecting CPC634 during freeze-drying when applied at an amount of 10 wt%. Considering this outcome, in the next step the feasibility of CPC634 freeze-drying with lower amounts of trehalose was studied in order to reduce excipient amount. Therefore, CPC634 was freeze-dried using 5 and 2.5 wt% of trehalose. Readouts upon reconstitutions were CPC634 size, PDI, and morphology, as assessed by DLS and TEM. As shown in Figure 4C,D and Figure S2A, Supporting Information, the mean size (65 nm), size distribution, and PDI (0.1) of CPC634 cryoprotected with 5 and 2.5 wt% of trehalose were similar to that of non-freeze-dried CPC634. In line with this, the TEM images and particle size analysis in Figure 4E,F and Figure S2C, Supporting Information, show that 5 and 2.5 wt% of trehalose efficiently cryoprotected CPC634, retaining a morphology and size identical to non-freeze-dried parental CPC634. In line with this, the TEM images and particle size analysis in Figure 4E,F and Figure S2C, Supporting Information, show that 5 and 2.5 wt% of trehalose efficiently cryoprotected CPC634, retaining a morphology and size identical to non-freeze-dried parental CPC634. The CPC634 freeze-dried cake cryoprotected with 5 and 2.5 wt% of trehalose had a residual moisture content of 1.8 ± 0.4 wt%, and could be successfully reconstituted within 5 min with a pH of 5.1, similar to the parental control formulation. These findings indicate that trehalose even at an amount as low as 2.5 wt% can provide proper protection of CCPM during freeze-drying. The drug content and in vitro drug release kinetics of these samples were not analyzed as no substantial changes in their mean size and PDI were observed compared to parental control formulation.

### 3.5 Towards industrial freeze-drying of CPC634

The freeze-drying process was optimized with the aim to further reduce the moisture content of the CPC634 freeze-dried cake to further slow down possible hydrolysis of ester bond between DTX and core of CPC634 upon long-term storage. This was carried out using an advanced freeze-dryer equipped with a Pirani gauge sensor, a Baratron capacitance manometer for vapor pressure analysis, and a product temperature sensor. To start with, cryoprotectant of the median concentration, i.e., 5 wt% trehalose, was selected from the abovementioned results. In this setting, the effect of commercially suitable buffer systems (20 mM succinate and citrate buffer systems, pH 5.0) was studied on CPC634 freeze-drying.

In line with the above findings, Figure 5A,B and Figure S2B, Supporting Information, clearly show that the mean size, size distribution, and PDI of CPC634 in the citrate and succinate buffer cryoprotected with 5 wt% trehalose were similar to those of non-freeze-dried control formulation.

In parallel, we investigated the effect of freeze-drying on DTX retention in CPC634 cryoprotected with 5 wt% trehalose in succinate and citrate buffer systems. As shown in Figure 5C, the amount of free DTX plus 7-epi-DTX had not changed after freeze-drying when cryoprotected with trehalose in citrate as well as succinate buffer.

The residual water content was found to be 0.055 and 0.060 wt% for CPC634 freeze-dried cakes cryoprotected with trehalose 5 wt% in combination with citrate and succinate buffer, respectively. Reconstitution analysis showed that reconstitution was 15 folds faster for the CPC634 freeze-dried cake cryoprotected with trehalose in citrate buffer (2 min) compared to succinate buffer (30 min). This could be due to elevated water penetration resistance in CPC634 freeze-dried cakes consisting trehalose and succinate buffer compared to CPC634 freeze-dried cakes consisting trehalose and citrate buffer. Decrease in the overall pore size and pore volume of freeze-dried cake can drastically delay reconstitution by impeding water penetration. Crystallization of buffer salts during freeze-drying decreases the pore size and volume of the freeze-dried cake thus, hindering water penetration. In this regard, succinate buffer shows higher
crystallization compared to citrate buffer after freeze-drying even in presence of trehalose at acidic pH.\textsuperscript{40,42,43} The reconstituted CPC634 cryoprotected with 5 wt% trehalose in combination with citrate (pH 5.1) and succinate (pH 5.0) buffer systems also showed identical pH as their respective non-freeze-dried parental control formulations.

Overall, these findings indicate that trehalose efficiently provides protection to CPC634 during freeze-drying when used with citrate buffer (pH 5.0). Further, our findings suggest that buffers play a crucial role in freeze-drying and that they can influence the outcome such as size and reconstitution time. The use of a more advanced shelf freeze-dryer at the industrial setting convincingly provided a well-controlled freeze-drying protocol and freeze-dried products with lower moisture content and shorter reconstitution time. These outcomes provide high confidence in further large-scale manufacturing development and optimal storage stability of CPC634 and other CriPec-based freeze-dried products.

4 | CONCLUSION

Our study exemplifies the feasibility of freeze-drying drug-entrapped CCPM upon the use of trehalose as a cryoprotectant. The lyophilized material was rapidly reconstitutable with unaltered pharmaceutical features such as size, PDI, drug retention, and drug release kinetics. Via additional validation in an industrial setting, our findings support large-scale development and future commercialization of freeze-dried CriPec-based CCPM drug products.

ACKNOWLEDGMENTS

This research was funded by the European Union (H2020-MSCA-ITN-2014 642028: NABBA and ERANET-EuroNanoMed-III: NSC4DIPG), by the German Research Foundation (DFG: GRK2375 [#331065168], SFB1066, and LA2937/4-1), by the German Federal Ministry of Education and Research (BMBF: PP-TNBC: 16GW0319K), by the European Research Council (ERC Consolidator Grant Meta-Targeting [#864121]), and by the Phospholipid Research Center: RBA-2019-076/1-1 (Heidelberg, Germany).

Open access funding enabled and organized by Projekt DEAL.

CONFLICT OF INTEREST

Cristal Therapeutics supplied test materials, performed partial analytical characterization, and covered external CDMO cost for the conducted study. Cristianne J. F. Rijken, Qizhi Hu, Claudio Colombo, and Michiel van Geijn were employees of Cristal Therapeutics during the conduct of the study. Jan Wit provided paid pharmaceutical consultancy to Cristal Therapeutics and contributed to the conducted study.

AUTHOR CONTRIBUTIONS

Tarun Ojha: Conceptualization; Data curation; Formal analysis; Methodology; Validation; Visualization; Writing – original draft; Writing – review and editing. Qizhi Hu: Conceptualization-Supporting; Data curation-Supporting; Formal analysis-Supporting; Investigation-Supporting; Validation-Supporting; Writing-review and editing-Supporting. Claudio Colombo: Conceptualization-Supporting; Data curation; Formal analysis; Investigation; Methodology; Project administration; Resources; Supervision; Validation; Visualization; Writing – original draft; Writing – review and editing. Jan Wit: Conceptualization-Supporting; Data curation; Formal analysis; Investigation; Methodology; Resources; Validation; Visualization; Writing – original draft; Writing – review and editing. Michiel Geijn: Conceptualization-Supporting; Data curation-Supporting; Formal analysis-Supporting; Investigation-Supporting; Methodology-Supporting; Resources-Supporting; Validation-Supporting; Visualization-Supporting; Writing original draft-Supporting; Writing-review & editing-Supporting. Mies van Steenbergen: Conceptualization-Supporting; Data curation-Supporting; Formal analysis-Supporting; Investigation-Supporting; Methodology-Supporting; Project administration-Supporting; Resources-Supporting; Software-Supporting; Validation-Supporting; Visualization-Supporting; Writing-original draft-Supporting; Writing-review & editing-Supporting. Mahsa Bagheri: Methodology; Writing – original draft; Writing – review and editing. Hiltrud König-Werner: Formal analysis; Investigation; Methodology; Resources; Software; Validation; Visualization; Writing – original draft; Writing – review and editing. Eva Buhl: Formal analysis-Supporting; Investigation-Supporting; Resources-Supporting; Software-Supporting; Validation-Supporting; Visualization-Supporting; Writing-original draft-Supporting; Writing-review & editing-Supporting. Ruchi Bansal: Resources; Writing – original draft; Writing – review and editing. Yang Shi: Investigation-Supporting; Writing-original draft-Supporting; Writing-review & editing-Supporting. Wim E. Hennink: Conceptualization-Supporting; Investigation-Supporting; Methodology-Supporting; Project administration-Supporting; Resources-Supporting; Supervision-Supporting; Validation-Supporting; Visualization-Supporting; Writing-original draft-Supporting; Writing-review & editing-Supporting. Gert Storm: Conceptualization-Supporting; Funding acquisition-Supporting; Investigation-Supporting; Methodology-Supporting; Project administration-Supporting; Resources-Supporting; Supervision-Supporting; Validation-Supporting; Visualization-Supporting; Writing-original draft-Supporting; Writing-review & editing-Supporting. Twan Lammers: Conceptualization-Supporting; Formal analysis-Supporting; Funding acquisition-Supporting; Investigation-Supporting; Methodology-Supporting; Project administration-Supporting; Resources-Supporting; Supervision-Supporting; Validation-Supporting; Writing-original draft-Supporting; Writing-review & editing-Supporting. Cristianne Rijken: Conceptualization-Supporting; Formal analysis-Supporting; Validation-Supporting; Writing-review & editing-Supporting. Mahsa Bagheri: Methodology; Writing – original draft; Writing – review and editing. Hiltrud König-Werner: Formal analysis; Investigation; Methodology; Resources; Software; Validation; Visualization; Writing – original draft; Writing – review and editing. Eva Buhl: Formal analysis-Supporting; Investigation-Supporting; Resources-Supporting; Software-Supporting; Validation-Supporting; Visualization-Supporting; Writing-original draft-Supporting; Writing-review & editing-Supporting. Ruchi Bansal: Resources; Writing – original draft; Writing – review and editing. Yang Shi: Investigation-Supporting; Writing-original draft-Supporting; Writing-review & editing-Supporting. Wim E. Hennink: Conceptualization-Supporting; Investigation-Supporting; Methodology-Supporting; Project administration-Supporting; Resources-Supporting; Supervision-Supporting; Validation-Supporting; Visualization-Supporting; Writing-original draft-Supporting; Writing-review & editing-Supporting. Gert Storm: Conceptualization-Supporting; Funding acquisition-Supporting; Investigation-Supporting; Methodology-Supporting; Project administration-Supporting; Resources-Supporting; Supervision-Supporting; Validation-Supporting; Visualization-Supporting; Writing-original draft-Supporting; Writing-review & editing-Supporting. Twan Lammers: Conceptualization-Supporting; Formal analysis-Supporting; Funding acquisition-Supporting; Investigation-Supporting; Methodology-Supporting; Project administration-Supporting; Resources-Supporting; Supervision-Supporting; Validation-Supporting; Visualization-Supporting; Writing-original draft-Supporting; Writing-review & editing-Supporting.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author.
REFERENCES

1. Shi, Y., Lammers, T., Storm, G., & Hennink, W. E. (2017). Physicochemical strategies to enhance stability and drug retention of polymeric micelles for tumor-targeted drug delivery. Macromolecular Bioscience, 01, 1600160.

2. Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018). Block copolymer micelles in nanomedicine applications. Chemical Reviews, 06, 6844–6892.

3. Talelli, M., Barz, M., Rijken, C. J., Kiessling, F., Hennink, W. E., & Lammers, T. (2015). Core-crosslinked polymeric micelles: Principles, preparation, biomedical applications and clinical translation. Nano Today, 02, 93–117.

4. Deng, C., Jiang, Y., Cheng, R., Meng, F., & Zhong, Z. (2012). Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: Promises, progress and prospects. Nano Today, 10, 467–480.

5. Fang, J., Nakamura, H., & Maeda, H. (2011). The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Advanced Drug Delivery Reviews, 03, 136–151.

6. Hu, Q., Rijken, C. J., van Gaal, E., Brundel, P., Kostkova, H., Etrych, T., Weber, B., Barz, M., Kiessling, F., Prakash, J., & Storm, G. (2016). Tailoring the physicochemical properties of core-crosslinked polymeric micelles for pharmaceutical applications. Advanced Drug Delivery Reviews, 12, 314–325.

7. Hu, Q., Rijken, C. J., Bansal, R., Hennink, W. E., Storm, G., & Prakash, J. (2015). Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles. Biomaterials, 06, 370–378.

8. Rijken, C. J., Snel, C. J., Schiffelers, R. M., van Nostrum, C. F., & Hennink, W. E. (2007). Hydrolyzable core-crosslinked thermosensitive polymeric micelles: Synthesis, characterization and in vivo studies. Biomaterials, 12, 5581–5593.

9. Talelli, M., Rijken, C. J., Hennink, W. E., & Lammers, T. (2012). Polymeric micelles for cancer therapy: 3 C’s to enhance efficacy. Current Opinion in Solid State and Materials Science, 12, 302–309.

10. Crie laard, B. J., Rijken, C. J., Quan, L., Van Der Wal, S., Altintas, I., Van Der Pot, M., Kruijtzer, J. A., Liskamp, R. M., Schiffelers, R. M., Van Nos trum, C. F., & Hennink, W. E. (2012). Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis. Angewandte Chemie International Edition, 07, 7254–7258.

11. Hu, Q., Van Gaal, E. V., Brundel, P., Ippel, H., Hackeng, T., Rijken, C. J., Storm, G., Hennink, W. E., & Prakash, J. (2015). A novel approach for the intravenous delivery of leuprolide using core-cross-linked polymeric micelles. Journal of Controlled Release, 04, 98–108.

12. Ojha, T., Pathak, V., Drude, N., Weiler, M., Rommel, D., Rütten, S., Geinitz, B., Van Steenbergen, M. J., Storm, G., Kiessling, F., & Lammers, T. (2019). Shelf-life evaluation and lyophilization of PBCA-based polymeric microbubbles. Pharmaceutics, 09, 433.

13. Abdelwahed, W., Degobert, G., Stainmesse, S., & Fessi, H. (2006). Freeze-drying of nanoparticles: Formulation, process and storage considerations. Advanced Drug Delivery Reviews, 12, 1688–1713.

14. Talsma, H., Cheng, J. Y., Lehrmann, H., Kursa, M., Ogris, M., Hennink, W. E., Cotten, M., & Wagner, F. (1997). Stabilization of gene delivery systems by freeze-drying. International Journal of Pharmaceutics, 11, 233–238.

15. Gray, S. A., Coler, R. N., Carter, D., & Siddiqui, A. A. (2016). Translational activities to enable NTD vaccines, progress in molecular biology and translational science. Elsevier.

16. Miyata, K., Kikizawa, Y., Nishiyama, N., Yamasaki, Y., Watanabe, T., Kohara, M., & Kataoka, K. (2005). Freeze-dried formulations for in vivo gene delivery of PEGylated polyplex micelles with disulfide crosslinked cores to the liver. Journal of Controlled Release, 12, 15–23.

17. Lee, S. W., Kim, Y. M., Cho, C. H., Kim, Y. T., Kim, S. M., Hur, S. Y., Kim, J. H., Kim, B. G., Kim, S. C., Ryu, H. S., & Kang, S. B. (2018). An open-label, randomized, parallel, phase II trial to evaluate the efficacy and safety of a cremophor-free polymeric micelle formulation of paclitaxel as first-line treatment for ovarian cancer: A Korean Gynecologic Oncology Group study (KGOG-3021). Cancer Treatment and Research: official Journal of Korean Cancer Association, 01, 195.

18. Matsumura, Y. (2008). Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Advanced Drug Delivery Reviews, 04, 899–914.

19. Chen, C., Han, D., Cai, C., & Tang, X. (2010). An overview of liposome lyophilization and its future potential. Journal of Controlled Release, 03, 299–311.

20. Van Winden, E. A. C., & Crommelin, D. J. A. (1997). Long term stability of freeze-dried, lyoprotected doxorubicin liposomes. European Journal of Pharmaceutics and Biopharmaceutics, 06, 295–307.

21. Cheng, J. Y., Van de Wetering, P., Talsma, H., Crommelin, D. J., & Hennink, W. E. (1997). Freeze-drying of poly[(2-dimethylamino)ethyl methacrylate]-based gene delivery systems. Pharmaceutical Research, 12, 1837–1840.

22. Yu, J., & Anchordoquy, T. J. (2009). Effects of moisture content on the storage stability of dried lipoplex formulations. Journal of Pharmaceutical Sciences, 09, 3278–3289.

23. Tang, X. C., & Pikal, M. J. (2004). Design of freeze-drying processes for pharmaceuticals: Practical advice. Pharmaceutical Research, 02, 191–200.

24. Mensink, M. A., Frijlink, H. W., van der Voort Maarschalk, K., & Hinrichs, W. L. (2017). How sugars protect proteins in the solid state and during drying (review): Mechanisms of stabilization in relation to stress conditions. European Journal of Pharmaceutics and Biopharmaceutics, 04, 288–295.

25. Crowe, L. M., Reid, D. S., & Crowe, J. H. (1996). Is trehalose special for preserving dry biomaterials? Biophysical Journal, 10, 2087–2093.

26. Tsinontides, S. C., Rajniak, P., Pham, D., Hunke, W. A., Placek, J., & Reynolds, S. D. (2004). Freeze drying—Principles and practice for successful scale-up to manufacturing. International Journal of Pharmaceutics, 08, 1–16.

27. Fonte, P., Reis, S., & Sarmento, B. (2016). Facts and evidences on the lyophilization of polymeric nanoparticles for drug delivery. Journal of Controlled Release, 03, 75–86.

28. Horn, J., & Friess, W. (2018). Detection of collapse and crystallization of saccharide, protein, and mannitol formulations by optical fibers in lyophilization. Frontiers in Chemistry, 01, 4.

29. Talelli, M., Rijken, C. J., Oliveira, S., van der Meel, R., en Henegouwen, P. M. V. B., Lammers, T., van Nostrum, C. F., Storm, G., & Hennink, W. E. (2011). Reprint of “Nonanob - Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting”. Journal of Controlled Release, 07, 93–102.

30. Patel, S. M., Toen, D., & Pikal, M. J. (2010). Determination of end point of primary drying in freeze-drying process control. Aaps PharmScitech, 03, 73–84.

31. Olsson, C., & Swenson, J. (2020). Structural comparison between sucrose and trehalose in aqueous solution. The Journal of Physical Chemistry B, 03, 3074–3082.

32. Bellavia, G., Cottone, G., Giuffrida, S., Cupane, A., & Cordone, L. (2009). Thermal denaturation of myoglobin in water— disaccharide matrixes: Relation with the glass transition of the system. The Journal of Physical Chemistry B, 08, 11543–11549.

33. Jain, N. K., & Roy, I. (2009). Effect of trehalose on protein structure. Protein Science, 01, 24–36.

34. Manjappa, A. S., Goel, P. N., Vekataraju, M. P., Rajesh, K. S., Makwana, K., Ukawala, M., Nikam, Y., Gude, R. P., & Murthy, R. S. R. (2013). Is an alternative drug delivery system needed for docetaxel? The role of
controlling epimerization in formulations and beyond. *Pharmaceutical Research*, 10, 2675–2693.

35. Kumar, D., Tomar, R. S., Deolia, S. K., Mitra, M., Mukherjee, R., & Burman, A. C. (2007). Isolation and characterization of degradation impurities in docetaxel drug substance and its formulation. *Journal of Pharmaceutical and Biomedical Analysis*, 03, 1228–1235.

36. de Chasteigner, S., Cavé, G., Fessi, H., Devissaguet, J. P., & Puisieux, F. (1996). Freeze-drying of itraconazole-loaded nanosphere suspensions: A feasibility study. *Drug Development Research* 06, 116–124.

37. Fonte, P., Araújo, F., Seabra, V., Reis, S., van de Weert, M., & Sarmento, B. (2015). Co-encapsulation of lyoprotectants improves the stability of protein-loaded PLGA nanoparticles upon lyophilization. *International Journal of Pharmaceutics*, 12, 850–862.

38. Fonte, P., Soares, S., Costa, A., Andrade, J. C., Seabra, V., Reis, S., & Sarmento, B. (2012). Effect of cryoprotectants on the porosity and stability of insulin-loaded PLGA nanoparticles after freeze-drying. *Biomatter*, 10, 329–339.

39. Beech, K. E., Biddlecombe, J. G., Van Der Walle, C. F., Stevens, L. A., Rigby, S. P., Burley, J. C., & Allen, S. (2015). Insights into the influence of the cooling profile on the reconstitution times of amorphous lyophilized protein formulations. *European Journal of Pharmaceutics and Biopharmaceutics*, 10, 247–254.

40. Lu, X., & Pikal, M. J. (2004). Freeze-drying of mannitol–trehalose–sodium chloride-based formulations: The impact of annealing on dry layer resistance to mass transfer and cake structure. *Pharmaceutical Development and Technology*, 01, 85–95.

41. Shalaev, E. Y., & Gatlin, L. A. (2010). The impact of buffer on solid-state properties and stability of freeze-dried dosage forms. In F. Jameel, & S. Hershenson (Eds.), *Formulation and process development strategies for manufacturing biopharmaceuticals*. John Wiley & Sons.

42. Desu, H. R., & Narishetty, S. T. (2013). Challenges in freeze–thaw processing of bulk protein solutions. In P. Kolhe, M. Shah, & N. Rathore (Eds.), *Sterile product development* (pp. 167–203). New York: Springer.

43. Sundaramurthi, P., & Suryanarayanan, R. (2011). The effect of crystallizing and non-crystallizing cosolutes on succinate buffer crystallization and the consequent pH shift in frozen solutions. *Pharmaceutical Research*, 02, 374–385.